KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Net Margin (2017 - 2025)

Sarepta Therapeutics (SRPT) has 12 years of Net Margin data on record, last reported at 25.14% in Q2 2025.

  • For Q2 2025, Net Margin rose 2326.0% year-over-year to 25.14%; the TTM value through Dec 2025 reached 21.25%, up 393.0%, while the annual FY2024 figure was 125.31%, 14923.0% up from the prior year.
  • Net Margin reached 25.14% in Q2 2025 per SRPT's latest filing, up from 6.43% in the prior quarter.
  • Across five years, Net Margin topped out at 194.66% in Q4 2022 and bottomed at 1145.76% in Q3 2022.
  • Average Net Margin over 5 years is 101.5%, with a median of 20.6% recorded in 2021.
  • Peak YoY movement for Net Margin: tumbled -112515bps in 2022, then soared 96377bps in 2023.
  • A 5-year view of Net Margin shows it stood at 108.94% in 2021, then skyrocketed by 279bps to 194.66% in 2022, then plummeted by -68bps to 61.34% in 2023, then tumbled by -110bps to 6.43% in 2024, then surged by 491bps to 25.14% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 25.14% in Q2 2025, 6.43% in Q4 2024, and 3.11% in Q3 2024.